Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Samsung, Biogen Idec Agree to Set Up Biosimilar Joint Venture Company
December 7, 2011
- Ethical Drug Sales Up 7% in October; 6th Monthly Increase in a Row: Crecon
December 7, 2011
- AnGes MG Reaches Agreement with Japanese, Korean Companies to Develop Therapeutic CIN Vaccine
December 6, 2011
- US Sunovion to Resubmit NDA for Antiepileptic Treatment STEDESA
December 6, 2011
- Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
- US Consulting Firm Says New Forecast Will Be Necessary for Anticancer Drug Market
December 6, 2011
- Taiho to Cooperate in Doctor-Led Clinical Trial
December 6, 2011
- Takeda Sets Up Global Vaccine Business Company to Enhance Global Operations
December 6, 2011
- OncoTherapy Confirms Safety of Cancer Vaccine OCV-105 in PI Trial
December 6, 2011
- Eisai’s US Research Subsidiary Starts Full Operation
December 5, 2011
- Pfizer, MSD Issue Repeated Warnings for Improper Use of Pneumococcal Vaccines Prevnar, Pneumovax
December 5, 2011
- Teijin Pharma Gets Good Response for Feburic from Medical Institutions: President Arao
December 2, 2011
- Pfizer President Umeda Says Steady Performance for Lyrica, “Business Objectives Achieved”
December 2, 2011
- Bayer, Regeneron Initiate PIII Trial for VEGF Trap-Eye in China
December 2, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 2, 2011
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…